Cargando…

Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study

BACKGROUND: Evidence has accumulated which suggests that sex steroids influence colorectal cancer development and progression. We therefore assessed the association of repeat polymorphisms in the estrogen receptor β gene (ESR2) and the androgen receptor gene (AR) with colorectal cancer risk and prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudolph, Anja, Shi, Hong, Försti, Asta, Hoffmeister, Michael, Sainz, Juan, Jansen, Lina, Hemminki, Kari, Brenner, Hermann, Chang-Claude, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232639/
https://www.ncbi.nlm.nih.gov/pubmed/25376484
http://dx.doi.org/10.1186/1471-2407-14-817
_version_ 1782344604963569664
author Rudolph, Anja
Shi, Hong
Försti, Asta
Hoffmeister, Michael
Sainz, Juan
Jansen, Lina
Hemminki, Kari
Brenner, Hermann
Chang-Claude, Jenny
author_facet Rudolph, Anja
Shi, Hong
Försti, Asta
Hoffmeister, Michael
Sainz, Juan
Jansen, Lina
Hemminki, Kari
Brenner, Hermann
Chang-Claude, Jenny
author_sort Rudolph, Anja
collection PubMed
description BACKGROUND: Evidence has accumulated which suggests that sex steroids influence colorectal cancer development and progression. We therefore assessed the association of repeat polymorphisms in the estrogen receptor β gene (ESR2) and the androgen receptor gene (AR) with colorectal cancer risk and prognosis. METHODS: The ESR2 CA and AR CAG repeat polymorphisms were genotyped in 1798 cases (746 female, 1052 male) and 1810 controls (732 female, 1078 male), matched for sex, age and county of residence. Colorectal cancer risk associations overall and specific for gender were evaluated using multivariate logistic regression models adjusted for sex, county of residence and age. Associations with overall and disease-specific survival were evaluated using Cox proportional hazard models adjusted for established prognostic factors (diagnosis of other cancer after colorectal cancer diagnosis, detection by screening, treatment with adjuvant chemotherapy, tumour extent, nodal status, distant metastasis, body mass index, age at diagnosis and year of diagnosis) and stratified for grade of differentiation. Heterogeneity in gender specific associations was assessed by comparing models with and without a multiplicative interaction term by means of a likelihood ratio test. RESULTS: The average number of ESR2 CA repeats was associated with a small 5% increase in colorectal cancer risk (OR = 1.05, 95% CI 1.01-1.10) without significant heterogeneity according to gender or tumoural ESR2 expression. We found no indication for an association between the AR CAG repeat polymorphisms and risk of colorectal cancer. The ESR2 CA and AR CAG repeat polymorphisms were not associated with overall survival or disease specific survival after colorectal cancer diagnosis. CONCLUSIONS: Higher numbers of ESR2 CA repeats are potentially associated with a small increase in colorectal cancer risk. Our study does not support an association between colorectal cancer prognosis and the investigated repeat polymorphisms. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-817) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4232639
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42326392014-11-16 Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study Rudolph, Anja Shi, Hong Försti, Asta Hoffmeister, Michael Sainz, Juan Jansen, Lina Hemminki, Kari Brenner, Hermann Chang-Claude, Jenny BMC Cancer Research Article BACKGROUND: Evidence has accumulated which suggests that sex steroids influence colorectal cancer development and progression. We therefore assessed the association of repeat polymorphisms in the estrogen receptor β gene (ESR2) and the androgen receptor gene (AR) with colorectal cancer risk and prognosis. METHODS: The ESR2 CA and AR CAG repeat polymorphisms were genotyped in 1798 cases (746 female, 1052 male) and 1810 controls (732 female, 1078 male), matched for sex, age and county of residence. Colorectal cancer risk associations overall and specific for gender were evaluated using multivariate logistic regression models adjusted for sex, county of residence and age. Associations with overall and disease-specific survival were evaluated using Cox proportional hazard models adjusted for established prognostic factors (diagnosis of other cancer after colorectal cancer diagnosis, detection by screening, treatment with adjuvant chemotherapy, tumour extent, nodal status, distant metastasis, body mass index, age at diagnosis and year of diagnosis) and stratified for grade of differentiation. Heterogeneity in gender specific associations was assessed by comparing models with and without a multiplicative interaction term by means of a likelihood ratio test. RESULTS: The average number of ESR2 CA repeats was associated with a small 5% increase in colorectal cancer risk (OR = 1.05, 95% CI 1.01-1.10) without significant heterogeneity according to gender or tumoural ESR2 expression. We found no indication for an association between the AR CAG repeat polymorphisms and risk of colorectal cancer. The ESR2 CA and AR CAG repeat polymorphisms were not associated with overall survival or disease specific survival after colorectal cancer diagnosis. CONCLUSIONS: Higher numbers of ESR2 CA repeats are potentially associated with a small increase in colorectal cancer risk. Our study does not support an association between colorectal cancer prognosis and the investigated repeat polymorphisms. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-817) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-07 /pmc/articles/PMC4232639/ /pubmed/25376484 http://dx.doi.org/10.1186/1471-2407-14-817 Text en © Rudolph et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rudolph, Anja
Shi, Hong
Försti, Asta
Hoffmeister, Michael
Sainz, Juan
Jansen, Lina
Hemminki, Kari
Brenner, Hermann
Chang-Claude, Jenny
Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study
title Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study
title_full Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study
title_fullStr Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study
title_full_unstemmed Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study
title_short Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study
title_sort repeat polymorphisms in esr2 and ar and colorectal cancer risk and prognosis: results from a german population-based case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232639/
https://www.ncbi.nlm.nih.gov/pubmed/25376484
http://dx.doi.org/10.1186/1471-2407-14-817
work_keys_str_mv AT rudolphanja repeatpolymorphismsinesr2andarandcolorectalcancerriskandprognosisresultsfromagermanpopulationbasedcasecontrolstudy
AT shihong repeatpolymorphismsinesr2andarandcolorectalcancerriskandprognosisresultsfromagermanpopulationbasedcasecontrolstudy
AT forstiasta repeatpolymorphismsinesr2andarandcolorectalcancerriskandprognosisresultsfromagermanpopulationbasedcasecontrolstudy
AT hoffmeistermichael repeatpolymorphismsinesr2andarandcolorectalcancerriskandprognosisresultsfromagermanpopulationbasedcasecontrolstudy
AT sainzjuan repeatpolymorphismsinesr2andarandcolorectalcancerriskandprognosisresultsfromagermanpopulationbasedcasecontrolstudy
AT jansenlina repeatpolymorphismsinesr2andarandcolorectalcancerriskandprognosisresultsfromagermanpopulationbasedcasecontrolstudy
AT hemminkikari repeatpolymorphismsinesr2andarandcolorectalcancerriskandprognosisresultsfromagermanpopulationbasedcasecontrolstudy
AT brennerhermann repeatpolymorphismsinesr2andarandcolorectalcancerriskandprognosisresultsfromagermanpopulationbasedcasecontrolstudy
AT changclaudejenny repeatpolymorphismsinesr2andarandcolorectalcancerriskandprognosisresultsfromagermanpopulationbasedcasecontrolstudy